Beyond that, prostate-specific membrane antigen PET/CT is particularly effective in the detection and staging of prostate cancer, while somatostatin receptor-PET/CT is highly effective for imaging neuroendocrine tumors, offering high sensitivity and specificity. Here, FOLH1 is linked to prostate cancer.